Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04167696
Title Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celyad Oncology SA
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

CYAD-02

Cyclophosphamide + Fludarabine

Age Groups: adult | senior
Covered Countries USA | BEL


No variant requirements are available.